HOME >> BIOLOGY >> NEWS
Tailor-made sugar coated proteins manufactured in novel E. coli system

The prospect of using bacteria to manufacture complex human proteins for use in therapeutic drugs is a step closer thanks to new research published today in Science.

Researchers from Switzerland and the UK report they have engineered the bacterium Escherichia coli to carry a vital piece of cell machinery that adds sugar molecules to newly synthesized proteins by a process known as glycosylation.

The finding opens up the possibility of producing complex human proteins such as Factor VIII and the hormone erythropoietin, which stimulates the production of red blood cells by stem cells in bone marrow. Both these proteins, which require the addition of sugar molecules to function properly, are currently produced by culturing mammalian cells, which can be a costly and technically difficult process.

The addition of sugars to proteins by glycosylation is crucial in defining their job in the body by helping them fold into a particular three-dimensional shape that determines how they interact with other proteins.

Simple bacterial cells normally do not possess the same type of cellular machinery used for glycosylation in higher organisms like humans. Until now this has restricted the types of human proteins that can be produced in bacteria.

The team of scientists from the Swiss Federal Institute of Technology, Zurich, the London School of Hygiene and Tropical Medicine and Imperial College London have shown that the bacterium Campylobacter jejuni uniquely contains glycosylation machinery similar to the type found in higher organisms. They have developed a technique of transferring this machinery into the E. coli bacterium, which is widely used in the industrial production of proteins.

Professor Anne Dell of Imperial College London said:

"We are only now beginning to understand the vital biological role sugars play in monitoring and guiding the day-to-day lives of the cells in our bodies. This work opens a path for th
'"/>

Contact: Judith H Moore
j.h.moore@ic.ac.uk
44-20-7594-6702
Imperial College London
28-Nov-2002


Page: 1 2

Related biology news :

1. Tailor-made cancer drugs: Wave of the future?
2. Sweet success in targeting sugar molecules to cells in living animals
3. Measuring blood sugar with a wave of the arm
4. Simple sugars make cell walls like steel
5. Candy canes, sugarplums or licorice for Christmas? Only one might stop cancer
6. Mutated protein combination tied to excessive sugar production
7. Groundbreaking research shows sugar to trigger growth
8. High sugar blood levels linked to poor memory
9. MIT sugars research affecting bypass patients, drug industry
10. Rushing fireball developed its own form of sugar digestion
11. Finding of key blood sugar controller could yield new diabetes drugs

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/1/2020)... SOMERSET, N.J. (PRWEB) , ... July 01, 2020 ... ... today announced that it had completed the purchase of Teva-Takeda Pharmaceuticals’ packaging facility ... with the company’s existing Japanese clinical supply facility located in Kakegawa, the new ...
(Date:6/28/2020)... ... June 25, 2020 , ... ... today announced that it has entered into a multi-year contract with Merus ... support their translational and clinical research strategy to discover and develop ground-breaking ...
(Date:6/25/2020)... (PRWEB) , ... June 24, 2020 , ... ... cloud-based enterprise software and software-driven clinical data services that accelerate drug development, is ... low-dose selinexor, an XPO1 inhibitor, in hospitalized patients with severe COVID-19. This is ...
Breaking Biology News(10 mins):
(Date:7/22/2020)... ... July 22, 2020 , ... Join experts from ... Sr. Manager Regulatory Solutions, in a one hour live webinar on Thursday, ... body in China for drugs and medical devices. Specifically, for medical devices, the NMPA ...
(Date:7/18/2020)... , ... July 16, 2020 , ... ... to aid in the early detection and prevention of high-burden diseases, and Centric ... US-based hospitals and healthcare organizations to utilize existing data in order to identify ...
(Date:7/10/2020)... , ... July 09, 2020 ... ... company, announced today that Massachusetts Institute of Technology (MIT) has expanded the ... license allows PathSensors to move into the point-of-care diagnostic market, focusing initially ...
(Date:7/7/2020)... ... ... R3 International is now offering stem cell therapy for Alzheimers dementia in Mexico ... patient's condition, treatment may be offered IV, intrathecal or with a combination. , A ... and the incidence continues to increase as individuals live longer. There is no cure, ...
Breaking Biology Technology:
Cached News: